Atropine ophthalmic - Cloudbreak Therapeutics
Alternative Names: 0.025% atropine sulphate; Atropine sulfate - Cloudbreak Therapeutics; CBT-009Latest Information Update: 10 Feb 2023
At a glance
- Originator Cloudbreak therapeutics
- Class Alcohols; Alkaloids; Antidotes; Azabicyclo compounds; Bridged bicyclo compounds; Cardiovascular therapies; Esters; Eye disorder therapies; Propanols; Small molecules; Toluenes; Tropanes
- Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
- 
          
            
              Orphan Drug Status
              NoOrphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. 
- New Molecular Entity No
Highest Development Phases
- Phase I/II Myopia
Most Recent Events
- 20 Jan 2023 Cloudbreak Therapeutics completes a phase I/II trial in Myopia (In volunteers) (Ophthalmic) (NCT05372991)
- 20 Jul 2022 Phase-I/II clinical trials in Myopia (In volunteers) in USA (Ophthalmic) (NCT05372991)
- 13 May 2022 Cloudbreak Therapeutics plans a phase I/II trial in Myopia (In volunteers) in July 2022 (Ophthalmic) (NCT05372991)
